Therapeutic target
Improvement of symptomatology.
Therapy recommendations
- Anti-infectives (local/local; antibiotics, antivirals).
- To prevent synechiae, mydriatics (pupil-dilating drugs; anticholinergics) and glucocorticoids
Further notes
- In patients with noninfectious uveitis intermedia, uveitis posterior, and panuveitis who respond inadequately to glucocorticoid therapy, adalimumab (human monoclonal antibody to tumor necrosis factor-α; TNF blocker) can be used. Adalimumab has delayed disease progression in two randomized trials.
